Table Graph
      published meta-analysis   sensitivity analysis   studies

control in COVID 19 hospitalized - Summary of results

OutcomeTE95% CInkI2ROBPub. bias death D28detailed resultsKalil (ACTT-3), 2021 1.74 [0.51; 5.93] 1.74[0.51; 5.93]Kalil (ACTT-3), 202110%969NAnot evaluable deathsdetailed resultsKalil (ACTT-3), 2021 1.74 [0.51; 5.93] SOLIDARITY (interferon), 2020 (REV) 0.86 [0.72; 1.04] 0.93[0.60; 1.44]Kalil (ACTT-3), 2021, SOLIDARITY (interferon), 2020 (REV)219%5,069moderatenot evaluable deaths (time to event analysis only)detailed resultsKalil (ACTT-3), 2021 1.74 [0.51; 5.93] 1.74[0.51; 5.93]Kalil (ACTT-3), 202110%969NAnot evaluable clinical improvementdetailed resultsKalil (ACTT-3), 2021 0.99 [0.87; 1.13] 0.99[0.87; 1.13]Kalil (ACTT-3), 202110%969NAnot evaluable clinical improvement (14-day)detailed resultsKalil (ACTT-3), 2021 1.01 [0.79; 1.29] 1.01[0.79; 1.29]Kalil (ACTT-3), 202110%969NAnot evaluable clinical improvement (time to event analysis only)detailed resultsKalil (ACTT-3), 2021 0.99 [0.87; 1.13] 0.99[0.87; 1.13]Kalil (ACTT-3), 202110%969NAnot evaluable death or ventilationdetailed resultsSOLIDARITY (interferon), 2020 (REV) 0.95 [0.81; 1.12] 0.95[0.81; 1.12]SOLIDARITY (interferon), 2020 (REV)10%4,100NAnot evaluable0.55.01.0relative treatment effectwww.metaEvidence.org2024-06-07 01:09 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 95,94,90,91 - treatments: 649,650,589,651,968 - roots T: 290

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons